Genomic and personalized medicine: foundations and applications

被引:346
作者
Ginsburg, Geoffrey S. [1 ]
Willard, Huntington F. [1 ]
机构
[1] Duke Univ, Duke Inst Genome Sci & Policy, Ctr Genom Med, Durham, NC 27708 USA
关键词
CLINICAL DECISION-SUPPORT; RETRACTED ARTICLE. SEE; CORONARY-HEART-DISEASE; GENE-EXPRESSION; FAMILY-HISTORY; BREAST-CANCER; TRANSPLANT RECIPIENTS; HEALTH-CARE; MANAGEMENT; RISK;
D O I
10.1016/j.trsl.2009.09.005
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The last decade has witnessed a steady embrace of genomic and personalized medicine by senior government officials, industry leadership, health care providers, and the public. Genomic medicine, which is the use of information from genomes and their derivatives (RNA, proteins, and metabolites) to guide medical decision making-is a key component of personalized medicine, which is a rapidly advancing field of health care that is informed by each person's unique clinical, genetic, genomic, and environmental information. As medicine begins to embrace genomic tools that enable more precise prediction and treatment disease, which include "whole genome" interrogation of sequence variation, transcription, proteins, and metabolites, the fundamentals of genomic and personalized medicine will require the development, standardization, and integration of several important tools into health systems and clinical workflows. These tools include health risk assessment, family health history, and clinical decision support for complex risk and predictive information. Together with genomic information, these tools will enable a paradigm shift to a comprehensive approach that will identify individual risks and guide clinical management and decision making, all of which form the basis for a more informed and effective approach to patient care. DNA-based risk assessment for common complex disease, molecular signatures for cancer diagnosis and prognosis, and genome-guided therapy and dose selection are just among the few important examples for which genome information has already enabled personalized health care along the continuum from health to disease. In addition, information from individual genomes, which is a fast-moving area of technological development, is spawning a social and information revolution among consumers that will undoubtedly affect health care decision making. Although these and other scientific findings are making their way from the genome to the clinic, the full application of genomic and personalized medicine in health care will require dramatic changes in regulatory and reimbursement policies as well as legislative protections for privacy for system-wide adoption. Thus, there are challenges from both a scientific and a policy perspective to personalized health care; however, they will be confronted and solved with the certainty that the science behind genomic medicine is sound and the practice of medicine that it informs is evidence based. (Translational Research 2009; 154:277-287)
引用
收藏
页码:277 / 287
页数:11
相关论文
共 65 条
[11]  
DHHS, 2009, MY HEALTHC
[12]  
*DHHS, 2008, REAL POT PHARM OPP C
[13]  
*DHHS, 2009, MY FAM HLTH PORTR
[14]  
DOUGLAS P, 2008, J CARDIOVASC T RES, P17
[15]   Blood gene expression profiling in liver transplant recipients with hepatitis C virus and posttransplantation diabetes mellitus [J].
Driscoll, C. J. ;
Cashion, A. K. ;
Hathaway, D. K. ;
Thompson, C. ;
Conley, Y. ;
Riely, C. ;
Xu, L. ;
Homayouni, R. .
TRANSPLANTATION PROCEEDINGS, 2006, 38 (10) :3646-3648
[16]   The economic implications of noninvasive molecular testing for cardiac allograft rejection [J].
Evans, RW ;
Williams, GE ;
Baron, HM ;
Deng, MC ;
Eisen, HJ ;
Hunt, SA ;
Khan, MM ;
Kobashigawa, JA ;
Marton, EN ;
Mehra, MR ;
Mital, SR .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (06) :1553-1558
[17]  
FDA, 2005, GUID IND PHARM DAT S
[18]  
*FDA, 2007, DRAFT GUID IND CLIN
[19]  
*FDA, 2009, TABL VAL GEN BIOM CO
[20]  
FDA, 2007, GUID IND FDA STAFF P